Lifshitz & Miller Law Firm Announces Investigation of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Im...

NEW YORK, March 18, 2014 /PRNewswire/ --

CytRx Corporation

Lifshitz & Miller  announces that a class action was filed in the United States District Court for the Central District of California, alleging CytRx Corporation ("CYTR") issued false and misleading statements during the period between November 22, 2013 and March 13, 2014.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that that numerous articles praising CytRx stock were paid stock promotions.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

DURECT Corporation

Lifshitz & Miller  announces that it is investigating potential claims against the officers and board of DURECT Corporation ("DRRX").  On February 12, 2014, the Company disclosed that the FDA had issued a Complete Response Letter for the Company's product candidate, POSIDUR.  The Complete Response Letter means that the FDA will not approve POSIDUR's application for marketing approval in its current form.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

Hastings Entertainment, Inc.

Lifshitz & Miller  announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Hastings Entertainment, Inc. ("HAST") to Draw Another Circle, LLC and Hendrix Acquisition Corp., which are each wholly-owned, directly or indirectly, by Joel Weinshanker in an all-cash transaction for $3.00 per share or approximately $21.4 million.

Lifshitz & Miller's investigation is focused on whether the HAST directors are acting in shareholders best interest.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

Immunomedics, Inc.

Lifshitz & Miller  announces that a class action was filed in the United States District Court for the District of New Jersey, alleging Immunomedics, Inc. ("IMMU") issued false and misleading statements during the period between May 9, 2013 and October 9, 2013.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that the Company and Takeda-Nycomed were embroiled in an on-going dispute regarding what Immunomedics considered to be an unacceptable delay in the development of Veltuzumab.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

NII Holdings, Inc.

Lifshitz & Miller  announces that a class action was filed in the United States District Court for the Eastern District of Virginia, alleging NII Holdings, Inc. ("NIHD") issued false and misleading statements during the period between February 25, 2010 and February 27, 2014.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that NIHD and NII Capital improperly concealed the Company's failing efforts to modernize its telecommunications network and expand its subscriber base.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

ATTORNEY ADVERTISING. © 2014 Lifshitz & Miller.  The law firm responsible for this advertisement is Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: [phone].  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz & Miller
Phone:   [phone]
Facsimile: 516-280-7376
Email: [e-mail]

SOURCE Lifshitz & Miller Law Firm

Copyright 2014 PR Newswire